Benign prostatic hyperplasia (BPH) - Market Insight, Epidemiology and Market Forecast - 2028
This report can be delivered to the clients within 7-10 Business Days
DelveInsight's 'Benign prostatic hyperplasia (BPH) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Benign prostatic hyperplasia (BPH) epidemiology and market outlook for the 7MM.
MARKETS COVERED
Benign prostatic hyperplasia (BPH) Understanding and Treatment Algorithm
The market report provides the overview of the Benign prostatic hyperplasia (BPH) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Benign prostatic hyperplasia (BPH) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Benign prostatic hyperplasia (BPH) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Benign prostatic hyperplasia (BPH) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Benign prostatic hyperplasia (BPH) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Benign prostatic hyperplasia (BPH) market.
Benign prostatic hyperplasia (BPH) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Benign prostatic hyperplasia (BPH) Report Insights
DelveInsight's 'Benign prostatic hyperplasia (BPH) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Benign prostatic hyperplasia (BPH) epidemiology and market outlook for the 7MM.
MARKETS COVERED
- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Benign prostatic hyperplasia (BPH) Understanding and Treatment Algorithm
The market report provides the overview of the Benign prostatic hyperplasia (BPH) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Benign prostatic hyperplasia (BPH) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Benign prostatic hyperplasia (BPH) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Benign prostatic hyperplasia (BPH) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Benign prostatic hyperplasia (BPH) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Benign prostatic hyperplasia (BPH) market.
Benign prostatic hyperplasia (BPH) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Benign prostatic hyperplasia (BPH) Report Insights
- Patient Population in Benign prostatic hyperplasia (BPH)
- Therapeutic Approaches in Benign prostatic hyperplasia (BPH)
- Benign prostatic hyperplasia (BPH) Pipeline Analysis
- Benign prostatic hyperplasia (BPH) Market Size and Trends
- Benign prostatic hyperplasia (BPH) Market Opportunities
- Impact of upcoming Therapies in Benign prostatic hyperplasia (BPH)
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices in Benign prostatic hyperplasia (BPH)
- Unmet Needs in Benign prostatic hyperplasia (BPH)
- Market Attractiveness
- Market Drivers and Barriers
- The report will help to develop Business Strategies by understanding the trends shaping and driving the Benign prostatic hyperplasia (BPH) market
- Organize sales and marketing efforts by identifying the best opportunities for Benign prostatic hyperplasia (BPH) market
- To understand the future market competition in the Benign prostatic hyperplasia (BPH) market.
1. REPORT INTRODUCTION
2. BENIGN PROSTATIC HYPERPLASIA (BPH) MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Benign prostatic hyperplasia (BPH) in 2016
2.2. Market Share Distribution of Benign prostatic hyperplasia (BPH) in 2028
3. DISEASE BACKGROUND AND OVERVIEW: BENIGN PROSTATIC HYPERPLASIA (BPH)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Benign prostatic hyperplasia (BPH) in 7MM
4.3. Total Prevalent Patient Population of Benign prostatic hyperplasia (BPH) in 7MM – By Countries
5. EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (BPH) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.1.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.1.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.1.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.1.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.4.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.4.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.4.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.4.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.5.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.5.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.5.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.5.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.6.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.6.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.6.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.6.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.7.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.7.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.7.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.7.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.8.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.8.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.8.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.8.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.9.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.9.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.9.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.9.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE BENIGN PROSTATIC HYPERPLASIA (BPH)
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. BENIGN PROSTATIC HYPERPLASIA (BPH): 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Benign prostatic hyperplasia (BPH)
12.2. 7MM Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH)
12.3. 7MM Market Sales of Benign prostatic hyperplasia (BPH) by Products
13. BENIGN PROSTATIC HYPERPLASIA (BPH): COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Benign prostatic hyperplasia (BPH) in United States
13.1.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in United States
13.1.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Benign prostatic hyperplasia (BPH) in Germany
13.2.1.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Germany
13.2.1.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Benign prostatic hyperplasia (BPH) in France
13.2.2.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in France
13.2.2.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Benign prostatic hyperplasia (BPH) in Italy
13.2.3.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Italy
13.2.3.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Benign prostatic hyperplasia (BPH) in Spain
13.2.4.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Spain
13.2.4.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Benign prostatic hyperplasia (BPH) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in United Kingdom
13.2.5.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Benign prostatic hyperplasia (BPH) in Japan
13.3.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Japan
13.3.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Indication Specific
2. BENIGN PROSTATIC HYPERPLASIA (BPH) MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Benign prostatic hyperplasia (BPH) in 2016
2.2. Market Share Distribution of Benign prostatic hyperplasia (BPH) in 2028
3. DISEASE BACKGROUND AND OVERVIEW: BENIGN PROSTATIC HYPERPLASIA (BPH)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Benign prostatic hyperplasia (BPH) in 7MM
4.3. Total Prevalent Patient Population of Benign prostatic hyperplasia (BPH) in 7MM – By Countries
5. EPIDEMIOLOGY OF BENIGN PROSTATIC HYPERPLASIA (BPH) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.1.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.1.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.1.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.1.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.4.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.4.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.4.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.4.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.5.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.5.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.5.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.5.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.6.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.6.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.6.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.6.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.7.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.7.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.7.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.7.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.8.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.8.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.8.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.8.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.9.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)
5.9.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)
5.9.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.9.6. Treatable Cases of the Benign prostatic hyperplasia (BPH)
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE BENIGN PROSTATIC HYPERPLASIA (BPH)
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. BENIGN PROSTATIC HYPERPLASIA (BPH): 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Benign prostatic hyperplasia (BPH)
12.2. 7MM Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH)
12.3. 7MM Market Sales of Benign prostatic hyperplasia (BPH) by Products
13. BENIGN PROSTATIC HYPERPLASIA (BPH): COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Benign prostatic hyperplasia (BPH) in United States
13.1.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in United States
13.1.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Benign prostatic hyperplasia (BPH) in Germany
13.2.1.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Germany
13.2.1.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Benign prostatic hyperplasia (BPH) in France
13.2.2.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in France
13.2.2.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Benign prostatic hyperplasia (BPH) in Italy
13.2.3.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Italy
13.2.3.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Benign prostatic hyperplasia (BPH) in Spain
13.2.4.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Spain
13.2.4.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Benign prostatic hyperplasia (BPH) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in United Kingdom
13.2.5.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Benign prostatic hyperplasia (BPH) in Japan
13.3.2. Percentage Share of drugs marketed for Benign prostatic hyperplasia (BPH) in Japan
13.3.3. Market Sales of Benign prostatic hyperplasia (BPH) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Indication Specific
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 6: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 7: Treatable Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 12: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 15: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 16: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 17: Treatable Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 22: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 27: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 31: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 32: Treatable Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 37: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 42:7MM- Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 45: United States-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 48: Germany-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 51: France-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 54: Italy-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 57: Spain-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 60:UK-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 63: Japan-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 1: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 6: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 7: Treatable Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 12: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 15: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 16: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 17: Treatable Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 22: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 27: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 31: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 32: Treatable Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 37: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 42:7MM- Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 45: United States-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 48: Germany-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 51: France-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 54: Italy-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 57: Spain-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 60:UK-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Table 63: Japan-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 7: Treatable Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 12: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 16: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 17: Treatable Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 22: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 27: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 32: Treatable Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 37: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 42:7MM- Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 45: United States-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 48: Germany-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 51: France-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 54: Italy-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 57: Spain-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 60:UK-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 63: Japan-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 1: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 7: Treatable Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 12: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 16: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 17: Treatable Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 22: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 27: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 32: Treatable Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 37: Treatable Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 42:7MM- Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 45: United States-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 48: Germany-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 51: France-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 54: Italy-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 57: Spain-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 60:UK-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Benign prostatic hyperplasia (BPH) in USD MM (2016-2028)
Figure 63: Japan-Market Share Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Benign prostatic hyperplasia (BPH) by Therapies in USD MM (2016-2028)
